相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Heme induces human and mouse platelet activation through C-type-lectin-like receptor-2
Joshua H. Bourne et al.
HAEMATOLOGICA (2021)
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Daniela Angst et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Interspecies differences in protein expression do not impact the spatiotemporal regulation of glycoprotein VI mediated activation
Joanne L. Dunster et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
A Comprehensive Tyrosine Phosphoproteomic Analysis Reveals Novel Components of the Platelet CLEC-2 Signaling Cascade
Irene Izquierdo et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases
Peter Blomgren et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Yuqin Song et al.
CLINICAL CANCER RESEARCH (2020)
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Paolo Ghia et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
Wei Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure
Abhishek Chauhan et al.
NATURE COMMUNICATIONS (2020)
Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, PhaseIITrial
Stanley Cohen et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin
Muhammad Usman Ahmed et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs
Ozgun Babur et al.
BLOOD (2020)
Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up
Judith Trotman et al.
BLOOD (2020)
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Mark Roschewski et al.
SCIENCE IMMUNOLOGY (2020)
Flow studies on human GPVI-deficient blood under coagulating and noncoagulating conditions
Magdolna Nagy et al.
BLOOD ADVANCES (2020)
A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors
Phillip L. R. Nicolson et al.
PLATELETS (2020)
The collagen receptor glycoprotein VI promotes platelet-mediated aggregation of β-amyloid
Lili Donner et al.
SCIENCE SIGNALING (2020)
Analysis of platelets from a diet-induced obesity rat model: elucidating platelet dysfunction in obesity
Maria N. Barrachina et al.
SCIENTIFIC REPORTS (2020)
The dual role of platelet-innate immune cell interactions in thrombo-inflammation
Julie Rayes et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
GPVI surface expression and signalling pathway activation are increased in platelets from obese patients: Elucidating potential anti-atherothrombotic targets in obesity
Maria N. Barrachina et al.
ATHEROSCLEROSIS (2019)
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)
Scott H. Watterson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib
Viola Denzinger et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab First-in-Human Healthy Volunteer Trial
Christine Voors-Pette et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Xavier Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
Kristina Busygina et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam et al.
BLOOD (2019)
Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial
Stefanie Schuepke et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction
Maria Bhatti et al.
THROMBOSIS RESEARCH (2019)
Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools
Sanae Ben Mkaddem et al.
FRONTIERS IN IMMUNOLOGY (2019)
From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks
Augusto Martins Lima et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Salmonella-induced thrombi in mice develop asynchronously in the spleen and liver and are not effective bacterial traps
Nonantzin Beristain-Covarrubias et al.
BLOOD (2019)
Functional significance of the platelet immune receptors GPVI and CLEC-2
Julie Rayes et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Platelet Glycoprotein VI Haplotypes and the Presentation of Paediatric Sepsis
Ahmed Asfari et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
James B. Bussel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans
Gasim Dobie et al.
BLOOD ADVANCES (2019)
Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?
Luise Goldmann et al.
BLOOD ADVANCES (2019)
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials
James Bussel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Platelets play an essential role in murine lung development through Clec-2/podoplanin interaction
Nagaharu Tsukiji et al.
BLOOD (2018)
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans
Kristina Busygina et al.
BLOOD (2018)
The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)
Jun Chen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Immobilized fibrinogen activates human platelets through glycoprotein VI
Pierre H. Mangin et al.
HAEMATOLOGICA (2018)
The contribution of platelet glycoprotein receptors to inflammatory bleeding prevention is stimulus and organ dependent
Julie Rayes et al.
HAEMATOLOGICA (2018)
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
Phillip L. R. Nicolson et al.
HAEMATOLOGICA (2018)
Dimeric Glycoprotein VI Binds to Collagen but Not to Fibrin
Mariam Ebrahim et al.
THROMBOSIS AND HAEMOSTASIS (2018)
Immobilized fibrinogen activates human platelets through glycoprotein VI
Pierre H. Mangin et al.
HAEMATOLOGICA (2018)
The contribution of platelet glycoprotein receptors to inflammatory bleeding prevention is stimulus and organ dependent
Julie Rayes et al.
HAEMATOLOGICA (2018)
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
Phillip L. R. Nicolson et al.
HAEMATOLOGICA (2018)
Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis
Astrid S. Clarke et al.
THROMBOSIS RESEARCH (2018)
Cobalt hematoporphyrin inhibits CLEC-2-podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice
Nagaharu Tsukiji et al.
BLOOD ADVANCES (2018)
Soluble GPVI is elevated in injured patients: shedding is mediated by fibrin activation of GPVI
Samantha J. Montague et al.
BLOOD ADVANCES (2018)
Platelet glycoprotein VI aids in local immunity during pneumonia-derived sepsis caused by gram-negative bacteria
Theodora A. M. Claushuis et al.
BLOOD (2018)
Glycoprotein VI in securing vascular integrity in inflamed vessels
Yacine Boulaftali et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)
Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling - Are Useful Drugs Already Available?
Jane F. Arthur et al.
DIABETES (2017)
Anti-GPVI Fab SAR264565 effectively blocks GPVI function in ex vivo human platelets under arterial shear in a perfusion chamber
Peter Florian et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Syk Activity Is Dispensable for Platelet GP1b-IX-V Signaling
Rachit Badolia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks
Kristell Lebozec et al.
MABS (2017)
Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis
John R. Stack et al.
PLOS ONE (2017)
Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation
Ann-Katrin Mojica Munoz et al.
THROMBOSIS AND HAEMOSTASIS (2017)
The podoplanin-CLEC-2 axis inhibits inflammation in sepsis
Julie Rayes et al.
NATURE COMMUNICATIONS (2017)
ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions
Heidrun Degen et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib
Alexander P. Bye et al.
BLOOD ADVANCES (2017)
CLEC-2 contributes to hemostasis independently of classical hemITAM signaling in mice
Elizabeth J. Haining et al.
BLOOD (2017)
Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model
Sherrill J. Slichter et al.
BLOOD (2017)
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib
Tracy E. Wiczer et al.
BLOOD ADVANCES (2017)
Fibrin and D-dimer bind to monomeric GPVI
Marie-Blanche Onselaer et al.
BLOOD ADVANCES (2017)
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib
Jeffrey A. Jones et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis
Holly Payne et al.
BLOOD (2017)
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Harriet S. Walter et al.
BLOOD (2016)
Syk Inhibition in Ischemic Stroke
Steven E. McKenzie
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
The Novel Oral Syk Inhibitor, Bl1002494, Protects Mice From Arterial Thrombosis and Thromboinflammatory Brain Infarction
Judith M. M. van Eeuwijk et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Mechanical circulatory support is associated with loss of platelet receptors glycoprotein Ibα and glycoprotein VI
P. Lukito et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Platelet Activation: The Mechanisms and Potential Biomarkers
Seong-Hoon Yun et al.
BIOMED RESEARCH INTERNATIONAL (2016)
Ibrutinib Inhibits Platelet Integrin a αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen
Alexander P. Bye et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: Haemostasis, platelet activation and antithrombotic therapy
Alyssa J. Moroi et al.
BIOCHEMICAL PHARMACOLOGY (2015)
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
Jeff Sharman et al.
BLOOD (2015)
Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation
Elmina Mammadova-Bach et al.
BLOOD (2015)
Fibrin activates GPVI in human and mouse platelets
Osama M. Alshehri et al.
BLOOD (2015)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
The expression of mouse CLEC-2 on leucocyte subsets varies according to their anatomical location and inflammatory state
Kate L. Lowe et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
Antiplatelet therapy in acute coronary syndromes
Erik L. Grove et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
The platelet Fc receptor, FcγRIIa
Jianlin Qiao et al.
IMMUNOLOGICAL REVIEWS (2015)
Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets
Jessica R. Hitchcock et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Prolonged and tunable residence time using reversible covalent kinase inhibitors
J. Michael Bradshaw et al.
NATURE CHEMICAL BIOLOGY (2015)
The role of platelets in inflammation
Mark R. Thomas et al.
THROMBOSIS AND HAEMOSTASIS (2015)
Targeting Glycoprotein VI and the Immunoreceptor Tyrosine-Based Activation Motif Signaling Pathway
David Stegner et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
CLEC-2 expression is maintained on activated platelets and on platelet microparticles
Eelo Gitz et al.
BLOOD (2014)
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Marie Levade et al.
BLOOD (2014)
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Julie R. McMullen et al.
BLOOD (2014)
Src family kinases: at the forefront of platelet activation
Yotis A. Senis et al.
BLOOD (2014)
New advances in treating thrombotic diseases: GPVI as a platelet drug target
Peng Jiang et al.
DRUG DISCOVERY TODAY (2014)
Copy Number Analysis of the Murine Platelet Proteome Spanning the Complete Abundance Range
Marlis Zeiler et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined In Vivo Depletion of Glycoprotein VI and C-Type Lectin-Like Receptor 2 Severely Compromises Hemostasis and Abrogates Arterial Thrombosis in Mice
Markus Bender et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Platelet receptors activated via mulitmerization: glycoprotein VI, GPIb-IX-V, and CLEC-2
Y. Ozaki et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke
Silvia Goebel et al.
PLOS ONE (2013)
The GPVI - Fc Fusion Protein Revacept Reduces Thrombus Formation and Improves Vascular Dysfunction in Atherosclerosis without Any Impact on Bleeding Times
Martin Ungerer et al.
PLOS ONE (2013)
The dimeric platelet collagen receptor GPVI-Fc reduces platelet adhesion to activated endothelium and preserves myocardial function after transient ischemia in mice
Tanja Schoenberger et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2012)
The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways
Julia M. Burkhart et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
The future of glycoprotein VI as an antithrombotic target
M. Zahid et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model
Michael P. Reilly et al.
BLOOD (2011)
Critical role for Syk in responses to vascular injury
Patrick Andre et al.
BLOOD (2011)
Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggregation Without Affecting General Hemostasis in Humans
Martin Ungerer et al.
CIRCULATION (2011)
Syk-dependent Phosphorylation of CLEC-2 A NOVEL MECHANISM OF HEM-IMMUNORECEPTOR TYROSINE-BASED ACTIVATION MOTIF SIGNALING
Sonia Severin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood
Nicholas Pugh et al.
BLOOD (2010)
Essential in Vivo Roles of the C-type Lectin Receptor CLEC-2 EMBRYONIC/NEONATAL LETHALITY OF CLEC-2-DEFICIENT MICE BY BLOOD/LYMPHATIC MISCONNECTIONS AND IMPAIRED THROMBUS FORMATION OF CLEC-2-DEFICIENT PLATELETS
Katsue Suzuki-Inoue et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Impact of glycoprotein VI and platelet adhesion on atherosclerosis-A possible role of fibronectin
Andreas Bueltmann et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2010)
GPVI and CLEC-2 in hemostasis and vascular integrity
S. P. Watson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
CLEC-2 is not required for platelet aggregation at arteriolar shear
C. E. Hughes et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis
Frauke May et al.
BLOOD (2009)
Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro
Julien Muzard et al.
FEBS JOURNAL (2009)
Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
Abdalla J. Mohamed et al.
IMMUNOLOGICAL REVIEWS (2009)
The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets
J. C. Spalton et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
The immunoadhesin glycoprotein VI-Fc regulates arterial remodelling after mechanical injury in ApoE(-/-) mice
Tanja Schoenberger et al.
CARDIOVASCULAR RESEARCH (2008)
Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura
E. E. Gardiner et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
The Modifier of hemostasis (Mh) locus on chromosome 4 controls in vivo hemostasis of Gp6-/- mice
Yann Cheli et al.
BLOOD (2008)
Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells
Katsue Suzuki-Inoue et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation
Sylvia Braselmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRγ deficiency
Pierre Mangin et al.
BLOOD (2006)
Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo
Christophe Dubois et al.
BLOOD (2006)
Local delivery of soluble platelet collagen receptor glycoprotein VI inhibits thrombus formation in vivo
Andreas Bueltmann et al.
THROMBOSIS AND HAEMOSTASIS (2006)
Laminin stimulates spreading of platelets through integrin α6β1-dependent activation of GPVI
O Inoue et al.
BLOOD (2006)
A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2
K Suzuki-Inoue et al.
BLOOD (2006)
GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism
Simon Lockyer et al.
THROMBOSIS RESEARCH (2006)
GPVI and integrin αIIβ3 signaling in platelets
SP Watson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Adhesion of human and mouse platelets to collagen under shear: a unifying model
JM Auger et al.
FASEB JOURNAL (2005)
Identification of residues within human glycoprotein VI involved in the binding to collagen -: Evidence for the existence of distinct binding sites
C Lecut et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Platelet adhesion signalling and the regulation of thrombus formation
JM Gibbins
JOURNAL OF CELL SCIENCE (2004)
Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced α2β1 levels or concomitant aspirin therapy
S Grüner et al.
CIRCULATION (2004)
Tec regulates platelet activation by GPVI in the absence of Btk
BT Atkinson et al.
BLOOD (2003)
Complementary roles of platelet glycoprotein VI and integrin α2β1 in collagen-induced thrombus formation in flowing whole blood ex vivo
MJE Kuijpers et al.
FASEB JOURNAL (2003)
Human platelet glycoprotein VI function is antagonized by monoclonal anti body-derived Fab fragments
C Lecut et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI)with collagen - A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen
Y Miura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice
B Nieswandt et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Phosphatidylinositol 3-kinase-dependent translocation of phospholipase Cγ2 in mouse megakaryocytes is independent of Bruton tyrosine kinase translocation
R Bobe et al.
BLOOD (2001)
分享论文
